Myfembree (Relugolix/Estradiol/Norethindr) Patent Expiration, LOE Window & CMS Spending

Myfembree (Relugolix/Estradiol/Norethindr) by Sumitomo America: FDA Orange Book core substance LOE 2033-09-27 (last listed 2042-11-05), 0 AB generics, $28.8M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSumitomo America
FDA Application & PathwayN214846 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2033-09-27
Last Listed Patent or Exclusivity Date2042-11-05
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$28.8M
2024 Medicare Part D Spend$2.1M
2024 Medicaid Spend$26.6M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 21.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sumitomo Pharma America across sibling Meru public-data platforms.